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S U M M A R Y
The Millennium Development Goal for tuberculosis (TB) is to stop the increase in incidence and halve the
mortality of TB between 1990 and 2015. This goal has now been reached on a global scale, although not in
the most affected region of Africa. The new target is TB elimination, deﬁned as one case of active TB per
one million population per year, which is to be reached before 2050. This review will discuss the main
tools in play, namely case-ﬁnding and new diagnostics, increased access and effectiveness of anti-TB
therapy (directly observed therapy, short course (DOTS)), preventive therapy for latent infection, and
vaccination. Each approach is discussed and a way forward in research and management is suggested.
 2014 The Author. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Achieving the control of tuberculosis (TB) is very difﬁcult in
resource-poor countries with a high burden of TB. Few and at times
poorly skilled health workers try to control the epidemic by
treating overt cases using the directly observed therapy supervised
approach (directly observed therapy, short course (DOTS)). This
will only treat the top of the TB iceberg;1 the transmission of TB
will continue due to delayed treatment, transmission from
undiagnosed patients, and from an increasing pool of latently
infected individuals who may progress to active disease. The
current agenda is to reach the Millennium Development Goal
(MDG) of stopping the increase in incidence and halving the
mortality of TB between 1990 and 2015, and this goal is likely to be
reached on a global scale but not in Africa.2,3
The next goal set by the World Health Organization (WHO) Stop
TB Program is the elimination of TB by 2050. Elimination is deﬁned
as zero disease in a deﬁned geographic area as a result of deliberate
efforts, with control measures needed to prevent reestablishment
of transmission; this is different from eradication, which is zero
disease globally as a result of deliberate efforts where control
measures are no longer needed.4 In terms of TB, elimination has
been deﬁned as less than one case of active smear-positive TB per* Corresponding author. Tel.: +45 20124958.
E-mail address: wejse@dadlnet.dk
http://dx.doi.org/10.1016/j.ijid.2014.11.020
1201-9712/ 2014 The Author. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).one million population per year.5 This will require a reduction in TB
incidence of 16% per year, however the current rate is 1%.6 This is
therefore not likely to happen using current approaches,6 hence
focus has been directed towards possible new technological
advances such as new diagnostics and a new TB vaccine.2,6,7
Nevertheless, for the global community to achieve the elimination
of TB, it will likely be necessary to utilize low-cost intervention
programs feasible in areas where TB reigns, and to target the
hidden part of the TB iceberg by addressing the latently infected.8
The path towards elimination of TB in high-burden areas may be
found using a number of approaches; these approaches are
reviewed below.
2. New diagnostics
One of the obstacles in targeting TB disease is the difﬁculty
associated with diagnosing active disease. Smear microscopy is the
most widely used method, but this has a sensitivity of only 50–
60%,9 leaving a large portion to be treated from clinical judgment
and radiography evaluation. Culture is the gold standard, but
requires a high degree of laboratory capacity, which is often not
available in high-burden areas. A major advance in diagnostics has
been automated PCR using the GeneXpert MTB/RIF platform,
which is more sensitive than smear microscopy and can also detect
drug resistance.9 Rolling-out this new diagnostic as a point-of-care
tool in peripheral health facilities has just been attempted in
several African countries, in a landmark trial testing Xpert MTB/RIFciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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X-ray. The results of the trial were somewhat disappointing, in that
the Xpert MTB/RIF arm did not place more patients on treatment
than the microscopy arm: 43% of people with suspected TB were
given treatment by day 56 in the Xpert MTB/RIF group compared to
42% in the microscopy group, although a slightly higher proportion
of those treated were culture-positive.10 Xpert MTB/RIF improved
same-day treatment initiation (23% in the Xpert group vs. 15% in
the microscopy group), and fewer culture-positive patients in the
Xpert MTB/RIF group who had a positive MTB/RIF test result did
not receive treatment (8% vs. 15%), halving drop-out. Nevertheless
there was no effect on the primary outcome, which was a
difference in morbidity according to the TBscore.11 Also, mortality
was 8% in both arms, but the study was not powered to detect
differences in mortality.
This promising diagnostic tool is deﬁnitely an advance, but in
terms of adding to the difﬁcult task of case-ﬁnding and reducing
the number of missed cases, it has brought little extra to the table,
and simpler less costly methods such as follow-up of the assumed
TB-negative (ATBneg; i.e., former TB suspects),12 or simple clinical
scores for TB suspects,13 may be more useful. Indeed for
eliminating TB, Xpert MTB/RIF will not be the magic bullet many
had hoped for and the associated costs are also prohibitive for
large-scale roll-out.14
3. Directly observed therapy, short-course (DOTS)
The treatment of active disease is a cornerstone in the ﬁght
against TB, and apart from saving the lives of those treated, it also
invariably reduces the transmission of TB. In light of this, scaling up
access to treatment has been a major focus in recent years, and is
still the primary focus in the WHO Global Report on TB.2 DOTS was
developed in the early 1990s as a response to the reemergence of
TB that was seen following the HIV epidemic. It consists of ﬁve
key programmatic elements: (1) A government commitment to
mobilize sufﬁcient resources for TB control. (2) Case detection
through passive case-ﬁnding using sputum smear microscopy in
patients with respiratory symptoms. (3) Treatment using standard
short-course chemotherapy regimens containing rifampin, admin-
istered under direct observation for at least the ﬁrst 2 months of
treatment. (4) Securing a regular supply of essential anti-TB drugs.
(5) Establishing a reliable monitoring, recording, and reporting
system for program supervision and evaluation.15
Yet, the central element for the patient is the direct observation
of treatment, which has been questioned because of the imposition
on patient autonomy,16 and this approach has not been found to be
more effective than self-supervision of treatment.17,18
Further, in terms of effectively combating TB and leading
the path towards elimination, DOTS alone will likely be a very
insufﬁcient measure;19,20 a number of approaches will be needed.
Mathematical modeling shows that even in the best of scenarios,
with a high case detection rate and optimal cure rates, DOTS will be
insufﬁcient to eliminate TB. At best it may more than halve the
incidence, but it will not reduce it by the factor of 1000 needed in
many high-burden areas.1,6
4. Preventive therapy of latent tuberculosis
Preventive treatment for latent TB infection (LTBI) was shown
to be effective 50 years ago in Alaska. Comstock et al. undertook
large-scale trials in the Inuit population and showed a long-lasting
effect on the TB burden in the population.21–23 This approach
is standard in most developed countries as part of contact
investigation, but has not so far been attempted in high-burden
areas except among the HIV-infected.17 Although recommended
by the WHO, it is not implemented in most high-burden areas dueto the fear of adverse events, poor adherence, and the facilitation of
drug resistance.24 Leading WHO ofﬁcers in the Stop TB department
recently concluded that further research is needed to establish its
cost-effectiveness and feasibility, especially in low-income and
middle-income countries.25 Yet, there is now growing evidence
that mass, community-wide screening for TB may be of beneﬁt in
some situations for enhanced case-ﬁnding.26,27 There is also
growing evidence that isoniazid preventive treatment (IPT) for the
latently infected is indeed feasible and effective, even in very low
resource settings with poor infrastructure.
We have shown in Guinea Bissau that adherence to IPT can be
quite high28 and that IPT in children in households with a recent
case of TB lowers mortality.29 However, a recent cluster random-
ized trial among 78 744 miners of three gold-mining companies in
South Africa showed that IPT had only a short-lasting effect on
overall TB incidence in this high-risk population with a high HIV
prevalence.30 Nevertheless, if looking only at the ﬁrst 9 months
when miners were actually taking isoniazid, the TB incidence in the
IPT cohort was signiﬁcantly lower (1.1 cases per 100 person-years)
compared to the control cohort (2.9 cases per 100 person-years). So
mass IPT did not reduce TB incidence at the community-level;
however, among those who were documented to receive IPT, the
TB incidence was reduced during the 9-month treatment period,
but the protective effect was lost immediately after treatment was
discontinued. An explanation for this may be the variable
participation of miners in the intervention clusters and a
suboptimal proportion of miners taking IPT. Also, the loss of
protection immediately after discontinuation of isoniazid may be
due to the reactivation of inadequately treated latent infections or
re-infection caused by high rates of ongoing transmission and it is
therefore less clear what the effect of IPT will be in populations
other than the extremely high-risk group of gold-miners.
5. New vaccines
Bacille Calmette–Gue´rin (BCG) is the most widely used vaccine
in the world, and in fact there is a high coverage rate in most high-
burden areas. It is known to be effective against TB meningitis and
miliary TB among children, but the effect wanes and there is
virtually no effect on adult TB. Disappointingly, large-scale mass
BCG vaccination has not had a long-lasting effect on TB
epidemiology.31 There are now several new vaccine candidates,
but so far no major breakthroughs have occurred.32 The only
vaccine candidate that has been tested so far in a phase 2B trial for
effectiveness is MVA85A, a BCG booster vaccine. The trial enrolled
2797 infants but showed no effect on the primary outcome, which
was TB incidence.33 Thirty-two children in the intervention arm
developed TB versus 39 in the placebo arm, hence a vaccine
efﬁcacy of 17% was seen, which was not signiﬁcant. There was also
no effect on TB infection determined by developing a positive
Quantiferon test. Two other vaccine candidates are now in phase
2B: AERAS-402/Crucell Ad35 in infants and GlaxoSmithKline’s GSK
M72 in adults. Both are post-exposure subunit booster vaccines
(http://www.aeras.org/candidates/). In addition, two candidates
from Statens Serum Institute are in phase 2; they both use
combined antigens with characteristics of early infection and
latency and have been found to protect mice against TB disease
before and after exposure to infection.34 The hopes for these
vaccines are high, but the results so far from the only one reaching
clinical efﬁcacy trials have been disappointing.
6. Discussion and conclusions
We are approaching 2015, the target year for the completion of
the MDGs. Although the overall target related to the MDGs of
halting and beginning to reverse the TB epidemic had already been
C. Wejse / International Journal of Infectious Diseases 32 (2015) 152–155154attained in 2004, the more important long-term elimination
target set for 2050 will not be met with present strategies and
instruments.
TB control by immunization certainly requires a vaccine that is
superior to the widely used BCG, for which efﬁcacy is variable and
often negligible in preventing pulmonary disease in adults. It is too
early to say if the new candidate vaccines will add to the TB
elimination agenda, but the current prospects for a fully protective
vaccine are not very good.
Better case-ﬁnding, optimized diagnostics, and effective
treatment schemes are all obvious and straightforward goals to
aim for, and all will undoubtedly serve the purpose of improving TB
control, but to hope that DOTS and new diagnostics will lead to
dramatic changes in TB incidence is likely not realistic. Many of the
DOTS components (e.g., government commitment, program
supervision, and evaluation) have been attempted for years –
with some success and a high importance given to the pursuit of
these goals – but they are very difﬁcult to achieve in many
high-burden countries where governments are failing to resolve a
number of high priority problems for the population.
This leaves us with one of the ‘old ideas’ in TB control:
preventive treatment.8 Despite the apparent failure of mass IPT to
prevent TB prevalence among South African miners, this ﬁnding
should be interpreted with caution. South African gold mines are
not the standard high-burden TB setting; the HIV prevalence is 30–
40%, TB notiﬁcation rates are above 4000/100 000,35 and the LTBI
prevalence is 90%,36 which is why they are labeled ‘TB factories’ by
mining activists. The best available evidence for the IPT effect on a
population scale is still the Comstock trials, where tuberculin skin
test (TST) positivity went from 80% in 1950 to 2% in 1963 among
Eskimo children aged <5 years in the Bethel area after mass IPT
was implemented.37 In areas with extremely high transmission
rates, IPT will only work while it is taken, but within a population
with much lower rates of LTBI and a limited pool of ongoing
transmission, the only way to target the pool of latently infected
people and avoid their contribution to active disease through
reactivation, is to treat them with IPT or perhaps even better with
short-course two-drug regimens.38 IPT may act in synergy with
conventional treatment programs and will also be more cost-
effective when used in combination.24
A commonly stated objection to IPT on a population-wide scale is
the risk of adding to the drug resistance problem in TB. The concern is
valid because non-compliance and inappropriate IPT may indeed
induce resistance.39 Nevertheless it is mostly something that has
been described in rare case reports,40 and not something seen in
trials testing the effects of IPT.41,42 A systematic review of 13 studies
with information on the development of drug resistance found no
such occurrence in four of the trials, and the combined risk estimate
of isoniazid-resistant TB after IPT was not signiﬁcant.43
The more recent Grading of Recommendations Assessment,
Development and Evaluation (GRADE) review for the 2011 WHO
IPT guidelines44 also found no statistically signiﬁcant increased
risk of isoniazid-resistant disease among patients previously
treated with IPT. In the USA, where IPT is used widely to treat
LTBI on a broad indication, the occurrence of isoniazid mono-
resistance has been stable and low over the past decades;45 this
also fails to support the development of serious drug-resistance
problems with the aggressive use of IPT. Mathematical modeling
has indicated that IPT for community-wide use may induce a
selective pressure, which over a time span of 50–100 years might
lead to increased isoniazid resistance.46 These concerns are not
prohibitive for the use of IPT on a population-wide scale, although
a strict methodology including rigorous testing for active TB and
social interventions to improve adherence are a prerequisite.47
In conclusion, conventional case-ﬁnding and treatment pro-
grams must continue and be implemented vigorously if we are todecrease the TB burden in the coming years. The WHO Stop TB
strategy is a cornerstone of global TB control. However, the
treatment of active TB, as a single strategy, is unlikely to bring the
incidence down to one case per million population by 2050, even
with very high rates of case detection. A simultaneous attack on
both active TB and latent infection would markedly increase the
chance of eliminating this disease during the twenty-ﬁrst century;
in particular, we need to gain much more knowledge on how to
bring preventive therapy into play in high-burden areas.
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